{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 56,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide uses a bar chart comparison to establish a benchmark for clinical efficacy in the IBD market.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/55",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.75,
        "x": 0.18,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical remission rates for Humira, Stelara, and Entyvio vs placebo",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "509a1600-059f-4986-8cbe-e8b778a6f258",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.15,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "legend",
      "text": "Treatment Arm (grey) vs Placebo (blue)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc4707d9-5736-4b53-bfde-cdad61ef255b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "table",
      "text": "Company and First US Approval year for the three drugs",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d4944bc-5cdb-44a4-b0e7-bbcc8fe77d84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "IMX-120 Opportunity: Inflammatory Bowel Disease (IBD) Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a62b571a-961f-4e0b-a2e8-f98bd63b3ca1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "8ff35154-ffe3-45cd-8c5e-25ce001c88c6",
      "evidence": "Direct comparison of clinical efficacy metrics against established market competitors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}